Bipap full details for md exams 10 marks answer
Reading File
Finding Sources
Searching the Web
BiPAP bilevel positive airway pressure complete details MD exam pulmonology
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive textbook data to write a full 10-mark MD exam answer. Let me compile everything:
BiPAP (Bilevel Positive Airway Pressure) - MD Exam 10-Mark Answer
1. Definition
BiPAP (Bilevel Positive Airway Pressure) is a form of Non-Invasive Positive Pressure Ventilation (NIPPV/NPPV) that delivers two alternating levels of positive airway pressure through a sealed mask (nasal, oronasal, or full-face), without requiring endotracheal intubation.
- "Bilevel" refers to two distinct pressure levels within a single respiratory cycle:
- IPAP (Inspiratory Positive Airway Pressure) - the higher pressure delivered during inhalation
- EPAP (Expiratory Positive Airway Pressure) - the lower pressure maintained during exhalation
- The term "BiPAP" is technically the proprietary name of a device by Philips Respironics; the generic term is BPAP (Bilevel PAP).
"BPAP assists the respiratory muscles by providing a pressure during inspiration, in addition to PEEP during expiration... Often referred to by its proprietary name BiPAP, BPAP is strongly recommended in cases of respiratory acidosis such as COPD exacerbations." - Murray & Nadel's Textbook of Respiratory Medicine
2. Mechanism of Action / Physiological Basis
| Component | Action | Physiological Effect |
|---|---|---|
| IPAP | Provides inspiratory pressure support | Reduces work of breathing; unloads respiratory muscles; increases tidal volume; counteracts intrinsic PEEP (iPEEP); augments alveolar ventilation to clear CO2 |
| EPAP | Acts as PEEP during expiration | Maintains FRC; prevents alveolar collapse; corrects hypoxemia by reducing intrapulmonary shunt; reduces left ventricular afterload (in heart failure) |
| Pressure Support (PS) | = IPAP - EPAP | The actual "driving pressure" that assists each breath |
Key physiological benefits:
- Reduces respiratory rate, allowing more complete lung emptying
- Overcomes intrinsic PEEP in COPD (air trapping)
- Improves ventilation-perfusion (V/Q) mismatch
- Reduces CO2 by increasing minute ventilation
- Reduces left ventricular transmural pressure - helpful in acute cardiogenic pulmonary edema
3. Modes of Delivery
| Mode | Description | Use |
|---|---|---|
| S (Spontaneous) | Patient triggers each breath; device delivers IPAP; no backup rate | Alert, cooperative patients |
| T (Timed) | All breaths are machine-triggered at set rate | Apneic or comatose patients |
| S/T (Spontaneous/Timed) | Patient triggers preferred; backup rate ensures minimum breaths/min if spontaneous rate drops | Most common clinical mode |
| BPAP-ST | S/T with backup rate | Central sleep apnea, neuromuscular disease |
| Auto-BPAP | Automatically adjusts IPAP/EPAP | OSA |
| ASV (Adaptive Servo-Ventilation) | Breath-by-breath pressure adjustment to counterbalance hyperventilation/hypoventilation | Complex CSA, Cheyne-Stokes respiration |
4. Initial Settings (Standard Protocol)
| Parameter | Starting Value | Titration Goal |
|---|---|---|
| IPAP | 10-15 cm H2O | Increase to 20-25 if CO2 retention persists; titrate for tidal volume, dyspnea, and patient-ventilator synchrony |
| EPAP | 5 cm H2O | Increase to 8 if morbid obesity or intrinsic PEEP; increase further for hypoxemia |
| FiO2 | 100% initially | Titrate to SpO2 88-92% (COPD); >94% (others) |
| Backup rate (S/T) | 12-16 breaths/min | Below patient's spontaneous rate |
| PS (IPAP-EPAP) | 5-10 cm H2O | Increase if hypercapnic; targets RR < 25/min |
Two Initiation Strategies:
- Low-High approach: Start IPAP 10, EPAP 5 → titrate up to achieve response (safer, better tolerated)
- High-Low approach: Start IPAP 20-25, EPAP 5 → titrate down (faster CO2 correction)
ABG should be checked within 1-2 hours of initiation to assess response.
5. Indications
A. Acute Indications
| Condition | Evidence/Recommendation |
|---|---|
| Acute COPD exacerbation with respiratory failure | Strongest evidence; first-line; reduces mortality, intubation rate, and hospital stay (Criteria: PaCO2 ≥45 mmHg AND pH ≤7.35, or severe dyspnea with accessory muscle use) |
| Acute cardiogenic pulmonary edema | Reduces preload and afterload; reduces intubation rate |
| Hypoxemic respiratory failure | Pneumonia, post-operative respiratory failure |
| Immunocompromised patients | Reduces infectious complications vs. intubation |
| Post-extubation respiratory failure | Prevents re-intubation |
| Acute hypercapnic respiratory failure | Neuromuscular disease, chest wall disorders |
B. Chronic/Home Indications
- Obstructive Sleep Apnea (OSA) - when CPAP fails or is not tolerated
- Central Sleep Apnea (CSA)
- Obesity Hypoventilation Syndrome (OHS)
- Chronic hypercapnic COPD (domiciliary NIV)
- Neuromuscular disease (ALS, Duchenne muscular dystrophy, spinal muscular atrophy)
- Chest wall disorders (kyphoscoliosis)
6. Contraindications
| Absolute Contraindications | Relative Contraindications |
|---|---|
| Respiratory/cardiac arrest | Hemodynamic instability unresponsive to fluids/vasopressors |
| Active vomiting/high aspiration risk | Agitation or uncooperative patient |
| Facial trauma/burns/recent facial surgery | Excessive secretions/inability to clear airway |
| Depressed mental status NOT related to high PaCO2 | Bowel obstruction |
| Inability to protect airway | Morbid obesity with positional difficulties |
| Inability to fit mask (facial deformity) |
7. Differences: BiPAP vs. CPAP
| Feature | CPAP | BiPAP |
|---|---|---|
| Pressure | Single constant level throughout cycle | Two levels: higher IPAP, lower EPAP |
| Inspiratory support | Minimal | Active inspiratory muscle unloading |
| CO2 clearance | Minimal | Active (via increased tidal volume) |
| Work of breathing | Partially reduced | Significantly reduced |
| Main indication | OSA, acute pulmonary edema | COPD exacerbation, hypercapnic failure, OSA-CPAP failure |
| Tolerance | Easier to exhale against | Better tolerated due to lower expiratory pressure |
8. Monitoring and Assessment of Response
Clinical parameters at 30-60 min:
- Decrease in respiratory rate (target < 25/min)
- Decrease in accessory muscle use
- Decrease in dyspnea score
- Improved SpO2
- Improved patient-ventilator synchrony
Objective parameters at 1-2 hours:
- Arterial Blood Gas (ABG): improvement in pH, PaCO2, PaO2
- If no improvement → consider escalation to invasive mechanical ventilation
Signs of BiPAP failure (indication for intubation):
- Persistent acidemia and hypercapnia
- Worsening consciousness/GCS decline
- Hemodynamic instability
- Inability to tolerate mask
- Massive secretions
9. Complications
| Complication | Cause / Notes |
|---|---|
| Mask discomfort/pressure sores | Most common; use proper interface fitting |
| Air leaks | Mask-face interface mismatch; causes patient-ventilator asynchrony |
| Aerophagia/gastric distension | Air swallowing at high pressures |
| Conjunctivitis | Upward air leak |
| Patient-ventilator asynchrony | Leaks cause prolonged inspiration (leak during inspiration) or auto-triggering (leak during expiration) |
| Barotrauma | Rare; at high IPAP |
| Aspiration | If airway protection is impaired |
| Claustrophobia/anxiety | Interface intolerance |
"Frequent asynchronies accounting for more than 10% of the respiratory efforts were present in 43% of patients undergoing NIV in an observational study." - Murray & Nadel's
10. BiPAP vs. Invasive Mechanical Ventilation
| Aspect | BiPAP (NIV) | Invasive MV |
|---|---|---|
| Airway | Mask - non-invasive | Endotracheal tube |
| Sedation | Usually not required | Required |
| Infection risk | Lower | Higher (VAP) |
| Communication | Preserved | Lost |
| Eating/drinking | Possible during breaks | Not possible |
| Failure rate | ~10-30% | N/A |
| When to prefer | Conscious, cooperative, reversible cause | NIV failure, hemodynamic instability, airway compromise, cardiac/respiratory arrest |
11. Special Situations
- Do-Not-Intubate (DNI) patients: BiPAP can serve as ceiling therapy or palliative support for dyspnea relief
- Acute asthma exacerbation: Increasingly used (with EPAP 5, IPAP titrated to 6-9 mL/kg tidal volume) but evidence is less robust than for COPD
- Treatment-emergent CSA on CPAP: Switch to BPAP-ST; if persistent, consider adaptive servo-ventilation
- Post-operative respiratory failure: Reduces re-intubation in high-risk surgical patients
Summary Table for Quick Recall
| Aspect | Key Points |
|---|---|
| Principle | IPAP (high) for inspiration + EPAP (low) for expiration via mask |
| Typical settings | IPAP 12-15, EPAP 5 cm H2O; increase PS (IPAP-EPAP) for CO2 |
| Best evidence | Acute COPD exacerbation with respiratory acidosis |
| Check ABG | Within 1-2 hours of initiation |
| Fail criteria | pH still low, worsening sensorium → intubate |
| Main complication | Mask leak → asynchrony; pressure sores |
Sources: ROSEN's Emergency Medicine, 9th ed. | Murray & Nadel's Textbook of Respiratory Medicine | Roberts & Hedges' Clinical Procedures in Emergency Medicine | Sabiston Textbook of Surgery
This is a shared conversation. Sign in to Orris to start your own chat.